VIM and cholangiocarcinoma: Clinical feasibility was investigated by analyzing whole blood specimens from non-small cell lung cancer (NSCLC) patients and cholangiocarcinoma patient, using the epithelial marker EPCAM and the epithelial–mesenchymal transition (EMT) biomarkers vimentin and MET.